[Efficacy of cabergoline in the treatment of macroprolactinoma].
Dupuy
O
O
Le Marec
E
E
Mayaudon
H
H
Rilminger
H
H
Bordier
L
L
Bauduceau
B
B
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D004873:Ergolines / Q000008:administration & dosage / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D010911:Pituitary Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D015175:Prolactinoma / Q000175:diagnosis / Q000188:drug therapy*; D013997:Time Factors
D000970:Antineoplastic Agents; D018491:Dopamine Agonists; D004873:Ergolines; D000077465:Cabergoline